ATAnouk Kirsten Trip

Anouk Kirsten Trip

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anouk Kirsten Trip has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of radiation dose on neurocognitive function and quality of life in long-term survivors of childhood brain tumour

    by Laura Toussaint, Anne Sophie Lind Helligsø, Ludvig Paul Muren, Ali Amidi, Rikke Hedegaard Dahlrot, Louise Tram Henriksen, Maja Vestmø Maraldo, Martin Skovmos Nielsen, Anouk Kirsten Trip, Lisa Maria Wu, et al.

    Background and purpose: Children treated with radiotherapy (RT) for a brain tumour often exhibit neurocognitive impairment and report lower quality of life (QoL) later in life. The aim of this nationwide cross-sectional cohort study was to explore the impact of RT dose to brain organs at risk (OARs) on neurocognition and QoL in long-term survivors of childhood brain tumours. Patient/material and methods: A total of 132 survivors of childhood brain tumours, diagnosed from 2001 to 2017 in Denmark, underwent neurocognitive tests and QoL questionnaires at least 5-years post-diagnosis. Neurocognitive assessments were complete and available for 86 patients (61 no-RT/25 RT), and QoL scores for 107 (79 no-RT/28 RT). Mann Whitney U-tests were used to compare scores between no-RT and RT groups. For scores impacted by RT, OAR-specific robust linear regressions were performed to evaluate RT dose effects while adjusting for potential confounders. Results: Clinically significant overall cognitive impairment was observed for 55% of the neurocognitive sub-cohort, with younger age at treatment time as a significant risk factor, while hydrocephalus status had no impact. There were no statistically significant differences on neurocognitive tests between the RT and no-RT group. However, patients treated with RT had significantly lower scores on the physical and social functioning QoL domains, with mean dose to the pituitary gland and left hippocampus, respectively, as significant predictors. Interpretation: This cross-sectional study indicates that RT dose-effects, particularly in the pituitary gland and left hippocampus, might contribute to reduced QoL in survivors of childhood brain tumours.


  • Site of first treatment failure after standard-of-care for newly diagnosed glioblastoma in a Danish cohort

    by Alice Mary Clarke, Slavka Lukacova, Rikke Hedegaard Dahlrot, Charlotte Aaquist Haslund, Aida Muhic, Jesper Folsted Kallehauge, Kasper Lind Laursen, Christian Rønn Hansen, Bob Smulders, Anouk Kirsten Trip

    Background: The aim of this nationwide study was to identify predictive factors for isolated local, non-local, and combined treatment failure in newly diagnosed glioblastoma patients. Methods: All adults with newly diagnosed glioblastoma in Denmark between 2014 and 2019 who were planned for long-course (chemo)radiotherapy were included. The MRI scan of first progression following RANO criteria was used to assess the site of failure. Multivariable multinomial logistic regression was applied to analyze the association between potential risk factors and the site of failure. Prediction models were derived. Results: We included 939 patients, of whom 758 had radiographic progression. Of those, 525 patients (69%) had isolated local failure, 114 (15%) non-local, and 119 (16%) combined. In patients with an MGMT promotor methylated (300) versus unmethylated (398) tumor, local failure was 66 versus 73%, non-local 21 versus 10%, and combined 12 versus 17%, respectively (P-value < .001). In multivariable analysis, MGMT promotor methylation status and tumor location were significantly associated with the failure site. In a model using MGMT promotor methylation status, tumor location, focality, extent of resection, and WHO performance status (poorly calibrated, C-index 0.63), the predicted probability (95% CI) of local failure varied from 0.47 (0.24 to 0.70) to 0.85 (0.74 to 0.97) between respective subgroups. That of non-local varied from 0.03 (0.00 to 0.07) to 0.36 (0.15 to 0.57) and combined from 0.05 (0.03 to 0.14) to 0.35 (0.05 to 0.65). Conclusions: It was not feasible to identify strong predictors for the site of first treatment failure, and hence, to derive an accurate prediction model. Isolated local failure was dominant in both patients with an MGMT promotor methylated and unmethylated tumor.

  • Open Access

    Identifying targetable alterations predictive of distant progression in glioblastoma patients undergoing standard therapy

    by Shivani Chiranth, Vincent Fougner, Ib Jarle Christensen, Anouk Kirsten Trip, Terkel Christiansen, Dorte Schou Nørøxe, Christina Westmose Yde, Anne Kiil Berthelsen, Benedikte Hasselbalch, Ulrik Lassen, et al.

    Background: Infiltrative growth is a hallmark of glioblastoma (GBM) and is a major factor in therapeutic failure. Distant progression is a surrogate marker for infiltrative growth and genetic variants predictive of distant progression may serve as novel treatment targets. The aim was to identify clinical, molecular, radiographic, and genetic factors associated with distant progression in GBM patients. Methods: From our prospective database, all consecutive GBM IDH wild type patients receiving standard therapy (Stupp regimen) from 2016 to 2021 at Rigshospitalet (Denmark) were included. Distant progression was defined as a new contrast-enhancing lesion > 2 cm from the initial lesion. Clinical, molecular, radiographic, and genomic covariates were assessed for association with time to distant progression using Cox analysis. Results: This single-center study included 353 patients, of whom 303 patients had radiographic progression. Distant progression was found in 66 patients (22%) and was associated with poor post-progression survival (P < .001). Unmethylated MGMT (hazard ratio [HR]: 2.54, 95% confidence interval [CI]: 1.62–3.97, P < .001), and multicentric disease at diagnosis (HR: 2.32, 95% CI: 1.28–4.20, P = .005) were associated with a shorter time to distant progression. In patients with a genomic tumor profile (n = 204), the NF1 gene alteration was identified as an independent predictor of distant progression (HR: 3.48, 95% CI: 1.48–8.21, P = .004) and poor survival. Conclusion: Distant progression is an aggressive progression pattern associated with a poor prognosis. Unmethylated MGMT, multicentric disease, and NF1 alteration independently predict distant progression. NF1 alteration may serve as a predictive biomarker for targeted treatment.


  • Open Access

    The effect of editing clinical contours on deep-learning segmentation accuracy of the gross tumor volume in glioblastoma

    by Kim M. Hochreuter, Jintao Ren, Jasper Nijkamp, Stine S. Korreman, Slávka Lukacova, Jesper F. Kallehauge, Anouk K. Trip


  • Patterns of care and survival in patients with multifocal glioblastoma: A Danish cohort study

    by Anouk Kirsten Trip, Rikke Hedegaard Dahlrot, Charlotte Aaquist Haslund, Aida Muhic, Anders Rosendal Korshøj, René Johannes Laursen, Frantz Rom Poulsen, Jane Skjøth-Rasmussen, Slavka Lukacova

    This Danish cohort study aims to (1) compare patterns of care (POC) and survival of patients with multifocal glioblastoma (mGBM) to those with unifocal glioblastoma (uGBM), and (2) explore the association of patient-related factors with treatment assignment and prognosis, respectively, in the subgroup of mGBM patients. Data on all adults with newly diagnosed, pathology-confirmed GBM between 2015-2019 was extracted from the Danish Neuro-Oncology Registry. To compare POC and survival of mGBM to uGBM, we applied multivariable logistic and Cox regression analysis, respectively. To analyze the association of patient-related factors with treatment assignment and prognosis, we established multivariable logistic and Cox regression models, respectively. In this cohort of 1343 patients, 231 had mGBM. Of those, 42% underwent tumor resection and 41% were assigned to long-course chemoradiotherapy. Compared to uGBM, mGBM patients less often underwent a partial (OR 0.4, 95%CI 0.2-0.6), near total (OR 0.1, 95%CI 0.07-0.2), and complete resection (OR 0.1, 95%CI 0.07-0.2) vs biopsy. mGBM patients were furthermore less often assigned to long-course chemoradiotherapy (OR 0.6, 95%CI 0.4-0.97). Median overall survival was 7.0 (95% CI 5.7-8.3) months for mGBM patients, and multifocality was an independent poor prognostic factor for survival (HR 1.3, 95%CI 1.1-1.5). In mGBM patients, initial performance, O[6]-methylguanine-DNA methyltransferase (MGMT) promotor methylation status, and extent of resection were significantly associated with survival. Patients with mGBM were treated with an overall less intensive approach. Multifocality was a poor prognostic factor for survival with a moderate effect. Prognostic factors for patients with mGBM were identified.


  • Open Access

    Patient Engagement in Research Scale (PEIRS-22): Danish translation, applicability, and user experiences

    by Mille Guldager Christiansen, Helle Pappot, Clayon Hamilton, Trine Lund-Jacobsen, Anne Wilhøft Kristensen, Sara Nordentoft, Beverley Lim Høeg, Pernille Bidstrup, Iben Husted Nielsen, Jane Ulstrup, et al.

    Background: Patient and Public Involvement (PPI) in health research is gaining increased attention and acceptance worldwide. Reliable measurements are crucial to accurately assess, monitor, and evaluate patient involvement efforts in research. The Patient Engagement in Research Scale (PEIRS-22) measures meaningful patient and family caregiver engagement in research. This study focuses on three primary objectives: (1) translation of the PEIRS-22 from English to Danish, followed by linguistic validation and cultural adaptation; (2) assessing the applicability of the Danish PEIRS-22; and (3) focus group interviews to explore the user experiences of PPI. Methods: A three-phase multi-method study was conducted. In phase one, the PEIRS-22 was translated, linguistically validated and culturally adapted to Danish. In phase two individuals from three distinct patient cancer advisory boards responded to the Danish version of PEIRS-22 to assess its applicability. Three focus group interviews were conducted in phase three, involving individuals from three patient cancer advisory boards. Results: The translation process resulted in a Danish version of PEIRS-22, conceptually and culturally equivalent to the English version. Overall, among individuals of the three advisory boards (n = 15) the applicability was found to be satisfactory, with no missing data and all items completed. The total PEIRS-22 score among the three advisory boards was 85.2 out of a possible 100, with higher scores indicating greater meaningful involvement. A nested sample of the three patient cancer advisory boards (n = 9) participated in focus group interviews. The analysis yielded four themes: (1) The Danish PEIRS-22 captured the intended cultural meaning and contributed to self-reflection, (2) Internal motivation is a driver for involvement (3), Involvement brought a personal sense of empowerment and (4) Meaningful involvement collaborations are fostered by a trustful atmosphere. Conclusions: The PEIRS-22 questionnaire has been translated, linguistically validated, and culturally adapted into Danish. We propose that the PEIRS-22 is now ready for use in Danish populations. This study provides a Danish version of the questionnaire that can be used to develop patient-centred practices and foster meaningful involvement and collaborations between patients and researchers in the field of cancer research in Denmark. Personal benefits of participating in PPI can vary, and we recommend using PEIRS-22 in conjunction with a qualitative approach to better explore perspectives on meaningful involvement. Trial registration: The study was registered prospectively on October 22, 2022, by the Danish Data Protection Agency (jr. nr. P-2022–528).


  • The impact of short-course hypofractionated radiotherapy on multimodality treatment utilisation, compliance, and outcome in glioblastoma patients: a Danish patterns of care study

    by Vishnuga Sivarasah Vamsi, Slavka Lukacova, Rikke Hedegaard Dahlrot, Trine Lignell Guldberg, Anders Rosendal Korshøj, Aida Muhic, Anouk Kirsten Trip

    The aim of this retrospective registry-based Danish patterns of care study was (1) to evaluate the real-world utilisation of short-course hypofractionated radiotherapy (HFRT) in glioblastoma (GBM) patients over time, and (2) to evaluate the impact of short-course HFRT by assessing trends in multimodality treatment utilisation, compliance, and outcome. Data of all adults with newly diagnosed pathology-confirmed GBM between 2011 and 2019 were extracted from the nationwide Danish Neuro-Oncology Registry. Short-course HFRT was defined as a fraction size of > 2 Gy to a planned dose of > 30 Gy. Patterns of care were assessed. To analyse trends in the assignment to short-course HFRT, and in radiotherapy (RT) compliance, multivariable logistic regression was applied. To analyse trends in survival, multivariable Cox regression was used. In this cohort of 2416 GBM patients, the utilisation of short-course HFRT significantly increased from ca. 10% in 2011 to 33% in recent years. This coincided with the discontinued use of palliative regimens and a decreased use of conventional fractionation. The proportion of patients proceeding to RT remained stable at ca. 85%. The proportion of patients assigned to chemoradiotherapy (CRT) remained stable at ca. 60%; the use of short-course hypofractionated CRT increased with ca. 10%, while the use of conventionally fractionated CRT decreased with ca. 10%. Compliance with conventionally fractionated and short-course HFRT was respective 92% and 93%, and significantly increasing in recent years. In the complete cohort, the median overall survival remained stable at ca. 11 months. Assignment to short-course HFRT was independently associated with shorter survival. In Denmark, the use of short-course HFRT significantly increased in recent years. Nonetheless, the overall utilisation of RT and chemotherapy did not increase on a population level. Nor did survival change. In contrast, compliance with both conventionally fractionated RT and short-course HFRT increased.